

R H I N O M E D

Not for release to U.S. wire services or distribution in the United States

Successful Completion of Retail Entitlement shortfall placement

6 May 2022: Melbourne, Australia.

Rhinomed Limited (ASX: RNO OTCQB:RHNMF) (**Rhinomed**) is pleased to announce that that it has been successful in today completing a placement of approximately AUD \$455,000 pursuant to the shortfall under the retail entitlement offer component of its recent accelerated non-renounceable pro rata capital raise. 2,394,735 new shares will be issued to new institutional and sophisticated investors on 11 May 2022 at AUD \$0.19 per share. No further shares will be issued under the shortfall capacity.

Bell Potter Securities Limited acted as Lead manager to the Placement.

This shortfall placement follows strong support for the Entitlement Offer, which raised approximately AUD \$4.468 million (as announced on 8 April 2022 and 4 May 2022).

The Board is very pleased with the support shown by both existing and new shareholders through the capital raising, which has provided a total of approximately \$4.923 million (before costs) in additional working capital for Rhinomed to bolster its manufacturing capabilities and provide working capital.

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global Follow us on Twitter @rhinomedceo	Rudi Michelson Monsoon Communications +61(0) 411 402 737 rudim@monsoon.com.au

About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)

Rhinomed Limited is a Melbourne, Australia based ASX listed nasal and airway technology company that has developed an innovative nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities.

Not an offer in the United States

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been, and will not be, registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.